

Hanoi, April 14th, 2025

**EXPLANATION OF BUSINESS PERFORMANCE
FOR THE FIRST QUARTER OF 2025**

Respectfully to: - State Securities Commission
- Hanoi Stock Exchange

Pursuant to:

- *Legal Regulations on Information Disclosure in the Securities Market;*
- *The self-prepared financial statements for Q1 2025 of Viet Nam Medicinal Materials Joint Stock Company;*

Viet Nam Medicinal Materials Joint Stock Company (Stock code: DVM) would like to provide an explanation for the changes in profit for the first quarter of 2025 compared to the first quarter of 2024 as follows:

No.	Content	Q1 2025 (VND)	Q1 2024 (VND)	Difference	
				Value (VND)	%
1	Net revenue	319,783,609,264	393,828,908,293	(74,045,299,029)	(18.80)
2	Profit after tax	12,296,114,634	8,268,977,399	4,027,137,235	48.70

The company's profit after tax in Q1/2025 increased by VND 4,027,137,235 compared to Q1/2024 due to the following reasons:

Although the net revenue in Q1/2025 decreased by VND 74,045,299,029 (equivalent to 18.80%) compared to the same period in 2024, the profit after tax increased due to reductions in selling expenses, administrative expenses, and financial expenses. As a result, the profit after tax in Q1/2025 rose by VND 4,027,137,235, equivalent to an increase of 48.70% compared to Q1/2024.

The above is the explanation provided by Vietnam Medicinal Materials Joint Stock Company regarding the business performance.

Best regards./.

Recipients:

- *As above;*
- *Archived at the office.*

GENERAL DIRECTOR



Vu Thanh Trung

